Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________ FORM 10-Q _________________________________________________ | | For the quarterly period ended June 30, 2023 | | --- | --- | | x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or | o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to Commissio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________ FORM 10-Q _________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to Commission File Number: ...

Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Benjamin Zeskind - President and Chief Executive Officer Brett Hall - Chief Scientific Officer Scott Barrett - Chief Medical Officer Mallory Morales - Vice President of Finance, Treasurer Conference Call Participants Swapnil Malekar - Piper Sandler Jeffrey Hung - Morgan Stanley Mark Breidenbach - Oppenheimer & Co. Inc. Michael Schmidt - Gug ...

Financial Performance - The company has incurred significant net losses for the past several years and expects to continue incurring substantial losses for the foreseeable future[19]. - The company requires substantial additional capital to finance its operations, and failure to raise such capital may lead to delays or reductions in research and drug development programs[19]. Regulatory and Development Challenges - The regulatory approval processes for product candidates are lengthy and unpredictable, which could substantially harm the business if approvals are not obtained[19]. - The company has a limited operating history in developing pharmaceutical products and has not completed any clinical trials, making it difficult to evaluate its current business and predict future success[19]. - The company may encounter substantial delays in completing the development and commercialization of its product candidates[19]. Dependency and Competition - The company is substantially dependent on the successful development of its current and future product candidates, as well as its proprietary technologies such as DCT and Fluency[19]. - The company faces significant competition, and if competitors develop more effective or less expensive products, it could negatively impact commercial opportunities[21]. External Risks - The COVID-19 pandemic and potential future pandemics could adversely impact the company's business, including clinical trials and supply chain[21]. - The company relies on third parties for conducting preclinical studies and clinical trials, and any failure by these parties could harm the business[21]. Commercialization Challenges - The company has never commercialized a product candidate before and may lack the necessary expertise and resources for successful commercialization[19].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40675 Immuneering Corporation (Exact name of registrant as specified in its charter) Delaware 26-1976972 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40675 Immuneering Corporation (Exact name of registrant as specified in its charter) 245 Main St. Second Floor ...

| --- | --- | --- | |--------------|-------|-------| | | | | | | | | | | | | | | | | | Investor | | | | Presentation | | | | | | | | Nasdaq: IMRX | | | | July 2022 | | | | | | | FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including w ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40675 Immuneering Corporation (Exact name of registrant as specified in its charter) 245 Main St. Second Floo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40675 Immuneering Corporation (Exact name of registrant as specified in its charter) 245 Main St. Second Floor Cam ...

Investor Presentation Ticker: IMRX February 2022 FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Immuneering Corporation's (the "Company") plans to develop, manufacture and commercialize ...